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Spending R90 million more per year to
implement new HIV risk reduction
measures for donated blood was
‘unavoidable’ because the health
ministry refused to negotiate on the use
of race as a valid risk indicator, says
Professor Anthon Heyns. 
The chief executive officer of the
South African National Blood
Transfusion Services (SANBS) told
Izindaba that the average risk of a black
South African being HIV-positive was
100 times greater than that of a white
compatriot.
‘Depending on the cohort you use, it
could be up to 150 times higher and that
is the basis for that part of the risk
selection method we’re using,’ he
added. He said that once the SANBS
made it clear to Health Minister Manto
Tshabalala-Msimang that her 31 January
deadline to produce a ‘reformed, non-
racial’ blood risk model was
scientifically impossible, she had
extended this to early
September.
In the meantime so-called
‘racial profiling’ in the
acceptance of blood would
continue, as it was the safest
and best currently known
modus operandi. Heyns told
Izindaba that testing and
validating a new blood risk
assessment model was
‘forced on us from a political
point of view’ – which he
understood.
Deadly odds
However, if the SANBS was
forced to treat all donors as
equal and abort the risk
management programme,
HIV/AIDS transmission
would leap from the current
internationally acclaimed
two infected recipients per
year to 30. From there it
would spiral out of control
to a baseline rate of 100
infected recipients per year.
‘I don’t know how long that
(100 per year) would take, but
that’s what could result,’ Heyns
warned.
Forensic pathologist Dr David
Klatzow waxed eloquent in his
objection to the government move,
saying the issue had ‘nothing’ to do
with racial stereotyping.
Many prominent medical colleagues
spoken to by Izindaba agreed with him,
but only off the record, for fear of being
branded racist. Klatzow said the issue
was purely one of risk management. ‘It
is entirely to do with providing the
safest possible blood products for
everybody in this country, irrespective
of race. To deny, in the approach to safe
blood, that the AIDS incidence follows
the socio-economic inequalities of the
past, is to take one tragedy and convert
it into a second tragedy, with the
additional element of farce thrown in!’
he said.
Heyns told Izindaba that he ‘thought’
blood from the new risk model they
were working on would be ‘relatively
safe’, but ‘we simply cannot say at the
moment because the jury is out. We’re
going to refine the model. The reality is
that we can’t scrap everything, so
implementation will require putting in
place various systems that ensure,
above all, that we do no harm to the
patient’.
The strongest risk indicator (race) had
been removed by government and the
SANBS was left with the next level
down – ‘donor status’.
‘Achilles heel’ of new model
The biggest challenge and a ‘possible
Achilles heel’ of the new model would
be to make sufficient blood safely
available to meet the country’s needs.
This was because the proposed model
prevented the SANBS from using blood
from first-time donors, which makes up
between 10% and 15% of the nation’s
total supply. ‘I really can’t say what the
outcome will be – if we can address the
question of shortage we’ll be fine,’ was
all he would conclude.
It was precisely because the SANBS
knew its current donor population
profile so well that it was confident in
using blood from first-time donors.
‘Now if we mix it with high and low
prevalence groups and exclude usage
from first-time donors we could face a
shortage,’ Heyns explained.
In future only plasma would be able
to be used from a first-time donation –
and then only after being placed in
quarantine until the donor returned a
second time and the fresh blood tested
negative, thus eliminating the window
period. This could not be done with red
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blood cells, which created the potential
‘Achilles heel’ of blood shortage.
At pains to emphasise that he saw the
SANBS as ‘partnering with
government’, Heyns said he doubted
that anybody in the medical community
would debate that evidence-based
medicine needed to be the ultimate
arbiter in the controversy.
‘Taking into account that we can
introduce this new expensive test and
that there are a couple of indicators that
we can combine with new test
technology, I want to be given an
opportunity to see whether in fact there
is an alternative or not. If there is, we’ll
have a win-win situation with
government.’
Safety ‘non-negotiable’
Asked where he would personally
‘draw the line’ if the alternative failed to
pass muster, Heyns quoted the medical
aphorism of ‘first do no harm’. ‘We
want to come up with an acceptable
solution within the context of South
Africa but I will not compromise on the
question of safety,’ he asserted. Asked
whether he might resort to the
Constitutional Court, he said this was
‘not on my horizon at this stage’.
‘We will devise, test and validate, see
what the outcome is and act
accordingly. The Constitution says that
all citizens should have access to
appropriate health care, life and bodily
integrity. Come the beginning of
September, either swords will be drawn
or there’ll be eternal peace – but for
now the jury remains out.’
What helped fan the emotional
cinders into a runaway blaze was a
weekend newspaper revealing that
blood donated by President Thabo
Mbeki in Durban in 2001 was discarded.
Mbeki failed to complete the mandatory
health questionnaire.
Tshabalala-Msimang demanded an
apology and accused the SANBS of
failing to ‘observe the principle of
confidentiality’ in its public discussion
of Mbeki’s records.
Heyns ‘felt abandoned’
Heyns and his medical director, Dr
Robert Crookes (who declined
comment), have enjoyed sparse open
public support from the medical
community since then. Heyns said he
felt abandoned by the South African
Medical Association and at one stage
had even considered resigning as a
member. None of SAMA’s senior
managers had approached him or his
colleagues for direct insight into the
controversy before joining the fray.
SAMA chairman, Dr Kgosi Letlape,
an arch critic of Tshabalala-Msimang,
this time backed her, stating
categorically that racial blood profiling
was ‘unacceptable and irresponsible’.
He also demanded that the SANBS ‘stop
justifying the process and apologise to
all South Africans’.
Letlape said SAMA supported the
‘vigilant measures’ the SANBS
employed in screening blood for
maximum safety and expressed the
hope that ‘satisfactory changes would
be made to their policy to avoid upset’.
Heyns responded, ‘I thought the
medical fraternity would seek some
understanding from us first and then
come out and support the health of
patients and the minimising of risk. I
could then have faced the issue feeling
much more comfortable’ .
Politicians lashed
Klatzow said he found it ‘intolerable’
that Professor Heyns, Dr Crookes and
other experts in the field should be
subjected ‘to the political whims of
people who in the past have shown
themselves to be ignorant in the
question of AIDS and AIDS policy’.
Political posturing would not achieve
the behaviour change needed to address
the pandemic and ‘all the garlic and
African potato’ that Tshabalala-
Msimang could provide, would not
alter that.
One highly placed source in the blood
transfusion world commented that
‘Klatzow has hit the nail on the head.
We need to use evidence-based,
statistically significant data’.
Also siding with Klatzow and
expressing empathy with the SANBS
was Professor Trefor Jenkins, Professor
Emeritus of Human Genetics at the
National Health Laboratory
Services/Witwatersrand University.
Heyns told Izindaba that if the new
model flies in September, safe blood
would cost 15% (or R100) more per unit
to produce and cost the blood purchaser
between 20% and 25% more. The
SANBS currently accepts between 
700 000 and 800 000 blood donations
per annum.
The R90 million costing is made up of
R80 million for the new testing
procedures (nucleic acid technology
screening) and R10 million for
implementing a new donor recruitment
strategy. Other safety criteria such as
age, gender, socio-economic
circumstances and geographic residence
will be looked at afresh.
Professor Jenkins said the issue was
‘about epidemiology and not individual
medical care’. Because of that, SANBS
policies were based on population
frequencies and decisions were centred
on protecting the maximum number of
people from infected blood.
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Racially sensitive counselling
Jenkins proposed longer counselling
during which individual donors were
told that if their blood tested positive,
only the plasma would be used and the
rest discarded. ‘The donor is performing
a noble act for the good of other people,
so it’s not an affront for a counsellor to
say to them upfront that their blood
cannot be accepted because they happen
belong to a high-risk group.’
Jenkins said the SANBS needed to
win over the donor and bypass
politicians unskilled in making medical
decisions. ‘Whatever the politicians say,
the doctor’s first ethical duty is to do no
harm – if I was prevented from
ensuring safety to the best of my ability
I’d either give up the job or do it
surreptitiously,’ he added.
He expressed deep concern that
doctors could be ‘bullied’ into unethical
practice. People who chose to be
affronted by the SANBS’ procedures
could simply stop being donors.
Jenkins cited a black letter writer in a
Johannesburg newspaper who said she
cared way less for political correctness
than she did for the opportunity for her
little daughter to receive the safest
possible blood. What was racist in the
past was when the SANBC only gave
blood donated by white people to white
people and that donated by black
people to black people, but this practice
had long since been stopped.
SAMA experts divided
Jenkins is an expert observer on
SAMA’s Human Rights, Law and Ethics
Committee, which debated the issue late
in February. He proposed a motion that
the SANBS be congratulated for
sustaining such a low infection rate for
so long, but was outvoted because this
would be seen to clash with Letlape’s
public stance.
Asked if Letlape was accurately
reflecting SAMA policy in his
comments, the chairman of SAMA’s
Health Policy committee, Professor John
Terblanche said the controversy was
being ‘dealt with by other committees’
and had not been before his.
The Chairman of SAMA’s Human
Rights, Law and Ethics Committee,
Professor Andries Stulting, said
Letlape’s statement was made via the
public affairs department ‘and not
through us – no, he didn’t consult us, it
was something they took up’. Stulting
said it was up to Heyns to contact
SAMA for support. ‘As far as I know he
never phoned anybody with the facts.
It’s a huge communications gap.’
His committee wanted ‘to do what’s
best for patients in the long run – we’re
very much against racism’.
Race debate ‘spurious’
Dr Judith Head, a senior lecturer in
UCT’s Department of sociology and co-
convener of the MPhil degree in
‘HIV/AIDS in Society’, said she
believed race to be a spurious indicator
and ‘a red herring’. 
Britain’s census data and health
statistics used socio-economic status
criteria with occupation as a proxy.
Morbidity and mortality for most
diseases in Britain were highest among
the least privileged – a situation
analagous to South Africa.  ‘Race is a
social construct and this controversy a
legacy of apartheid thinking,’ she said.
The government intervention was a
‘golden opportunity’ for the SANBS to
look at some of its ‘rather lazy
assumptions instead of fighting a
defensive rearguard action’.
While public safety was clearly of
paramount concern, the controversy
could end up building national unity
instead of undermining it. ‘It will be
wonderful if this stimulates more
rigorous research and reflection,’ she
added.
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CURRENT BLOOD DONATION
MODEL (as set out by SANBS
CEO, Professor Anthon Heyns)
1.   All donors are treated equally
(with the necessary respect and
courtesy). Blood is taken if
they comply with health safety
criteria for donor and
recipient. Whatever ‘colour’
you are, blood is taken. If
safety criteria are met, some
part of the blood is always
used.
2.   Once the blood enters SANBS,
‘the entire focus changes – it’s
about the recipient and we do
everything to the blood that
would satisfy their safety
needs. This includes testing.
We stratify the donation
(nothing to do with the donor),
in order to minimise the risk to
the patient. This is where we
use race as an indicator not a
factor.’ Four main safety
indicators: race, donor status,
gender, and the location of the
clinic where the blood was
taken (which, because of
existing demographics is
inherently racial). Blood is then
classified and all donations are
put into cohorts. The risk is
classified and blood products
are issued according to a strict
hierarchy of safety.
3.  The lowest-risk blood available
is then issued indiscriminately.
Heyns said of the new enforced
measures: ‘If you use a road
safety analogy – it’s like saying
you may not discriminate in
terms of speed. So you’re left
with just traffic lights, safety
bags and safety belts’.
